Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial
Year: 2014
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: The Lancet Oncology
Authors: Robert J Motzer, Camillo Porta, Nicholas J Vogelzang, Cora N Sternberg, Cezary Szczylik, Jakub Zolnierek, Christian Kollmannsberger, Sun Young Rha, Georg A Bjarnason, Bohuslav Melichar, Ugo De Giorgi, Viktor Grünwald, Ian D Davis, Jae-Lyun Lee, Emilio Esteban, Gladys Urbanowitz, Can Cai, Matthew Squires, Mahtab Marker, Michael M Shi, Bernard Escudier
Institutions: Memorial Sloan Kettering Cancer Center, Istituti di Ricovero e Cura a Carattere Scientifico, Comprehensive Cancer Centers of Nevada, Azienda Ospedaliera San Camillo-Forlanini, The Maria Sklodowska-Curie National Research Institute of Oncology, BC Cancer Agency, Yonsei University, Yonsei Cancer Hospital, Sunnybrook Health Science Centre, Sunnybrook Hospital, Odette Cancer Centre, Palacký University Olomouc, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Medizinische Hochschule Hannover, Eastern Health, Monash University, Asan Medical Center, Hospital Universitario Central de Asturias, Novartis (Switzerland), Institut Gustave Roussy
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Award: Cancer Center Support Grant
OpenAlex ID: W2127385754